MVT-100新型超声增强剂的临床前研究
本研究在临床前比较新型微泡超声增强剂MVT-100与Perflutren的理化及体内特性。MVT-100 zeta电位近中性、粒径分布更集中、储存稳定性更优、肾脏滞留更低,猪超声心动图显示后期显影更持久且声影无差异。
要点
- MVT-100粒径分布更集中(多分散指数0.114 vs 0.159,p=0.048)。
- 加速储存后MVT-100磷脂损失仅2.05%,远低于Perflutren的13.10%。
- 小鼠肾脏滞留MVT-100约为Perflutren的1/2.5。
关键影像表现/征象
- MVT-100 zeta电位近中性(+0.5 ± 0.1 mV),Perflutren为负电位(-4.2 ± 2.0 mV)。
- MVT-100粒径分布更集中,多分散指数0.114 ± 0.012,低于Perflutren的0.159 ± 0.036(p=0.048)。
- 40°C储存4周后MVT-100总磷脂损失2.05%,Perflutren损失13.10%。
- 小鼠肾脏滞留MVT-100显著低于Perflutren,约低2.5倍。
- 猪超声心动图显示MVT-100后期心室显影更高更持久(主效应p<0.001,时间×药剂交互p<0.001),声影无显著差异(p>0.99)。
临床应用与阅片要点
- 临床前数据显示MVT-100后期显影更持久,未来或有助于延长心脏超声增强窗口。
- MVT-100肾脏滞留更低,提示潜在安全性优势,但需临床研究验证。
- MVT-100声影与Perflutren无差异,右心显影时仍需注意声影干扰。
局限性
- 研究为临床前动物实验,结果不能直接外推至人体。
- 样本量未报告,统计效能有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVE: Over the past decades, many investigations have used perfluorocarbon (PFC)-based contrast products to enhance ultrasound (US) imaging. Currently octafluoropropane (OFP), decafluorobutane, and sulfur hexafluoride or a combination of those gases is used for the preparation of ultrasound enhancing agents (UEA). This study reports the development of MVT-100, a novel microbubble ultrasound enhancing agent (UEA) designed for improved stability, safety, and imaging performance. The objective of these studies was to fully characterize and compare the biophysical, chemical and in vivo properties of the new UEA (herein referred to as MVT-100) as compared with the well-known and widely utilized UEA known as perflutren lipid microspheres (Perflutren) (commercialized under the name of Definity®).
METHODS: Analytical methods were used to characterize the MBs. Low mechanical index (MI) contrast-enhanced ultrasound was performed in mice and pigs.
RESULTS: Comparison of Perflutren MB with MVT-100 MB showed similarities of the products in their overall particle numbers, gas content, osmolality, pH and phospholipid concentrations. However, MVT-100 exhibited a zeta potential that was essentially neutral (+0.5 ± 0.1 mV), compared with the negative zeta potential of Perflutren (-4.2 ± 2.0 mV), a tighter size distribution and lower polydispersity index (0.114 ± 0.012 vs. 0.159 ± 0.036, p = 0.048). Under accelerated storage conditions (40°C for 4 weeks), MVT-100 demonstrated markedly greater lipid stability, with only 2.05% loss of total phospholipid content compared with 13.10% for Perflutren. Murine renal retention studies showed that MVT-100 MB exhibited significantly lower (∼2.5 fold) renal retention in the kidney as compared with Perflutren. In porcine studies, MVT-100 hemodynamic parameters were identical to those of Perflutren. Echocardiographic porcine studies showed that ventricular opacification and endocardial border delineation following MVT-100 administration were comparable between agents at early time points, with higher and more sustained opacification with MVT-100 at later time points (generalized linear mixed model: main effect of agent p < 0.001, time × agent interaction p < 0.001) and no evidence of a significant difference in acoustic shadowing between agents (p > 0.99).
CONCLUSIONS: MVT-100 is a novel UEA that exhibits promising properties as a new imaging agent for contrast echocardiography with appealing storage conditions.
引用
- Meuillet EJ, Lusk J, Tadevich H, et al. Preclinical Studies of MVT-100, A Novel Ultrasound Enhancing Agent. Ultrasound Med Biol. 2026. PMID: 42951792. doi:10.1016/j.ultrasmedbio.2026.09.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。